ITGAX and Bloom syndrome: Within the SiglecF–CD11b+ MoM group, the number of SiglecF–CD11c+CD11b+ macrophages was increased in the BLM model, but the intravenous administration of MSCs significantly reduced this subset (Fig. 7D).